CARsgen Therapeutics and Huadong Medicine (Hangzhou) will collaborate on the commercialisation of CARsgen's BCMA CAR-T product CT053 in mainland China.  CT053 (zevorcabtagene autoleucel, Zevor-cel) is CARsgen's lead drug candidate and an autologous CAR T cell product treating relapsed/refractory multiple myeloma (R/R MM).  Dr Zonghai Li, Chairman of the Board, Chief Executive Officer, and Chief Scientific […]

To read this content in full, you need to login.

Not yet a DDW member? Join now for FREE – it takes less than 2 minutes!